A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
about
Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugsState-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical dataA pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCIThe effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study.Current antiplatelet treatment strategy in patients with diabetes mellitus.Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyA study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCIIncreased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndromeSnapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetesEffect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study.Prasugrel resistance: fact or fiction.TRITON and beyond: new insights into the profile of prasugrel.Current concepts on coronary revascularization in diabetic patients.Antiplatelet options for secondary prevention in acute coronary syndromes.InforMatrix: ADP antagonists in acute coronary syndromes.Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials.Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Overcoming aspirin treatment failure in diabetes.Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease.Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.Platelet function profiles in patients with diabetes mellitus.Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis.P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal useThe pharmacodynamics of antiplatelet compounds in thrombosis treatment.A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures.Why we need intravenous antiplatelet agents.P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?Towards personalized medicine based on platelet function testing for stent thrombosis patients
P2860
Q26795403-6B2A8AC2-59E9-4128-8748-CE93DEAA84B3Q30373414-703DCB1C-A70B-4105-B6EA-1F9C989AE28DQ30660247-F143472B-9FCC-4295-8910-7C782C182455Q34761979-F5097F20-E7CE-4D02-BB87-0EA1CC88DCA1Q35073622-F8903B92-86C1-4697-A317-DC6607969799Q35544048-F8F3AA4F-37C7-43EB-ADCE-B2E5BD12480BQ35755253-88CB4D29-2905-4B85-AA9A-0C33DD039554Q35764145-349C3371-0346-4600-84F6-050371ED2DD3Q36094523-CA7C5890-DA0A-4DE2-8A06-DB556DAEE47BQ36720281-D5C2FFF7-DAAE-413A-B965-AF36BE722B41Q36841959-26277F46-CFEB-4AB9-B695-1636321D2785Q36924615-C65917D4-03CB-4CE8-82E6-55AAD02E17A7Q37022618-22FA481F-8494-414B-8AFF-5B3054337799Q37429557-71FCC57B-C746-4279-B802-5926B069A1E2Q37905028-E879B35A-1E16-4316-912C-912BCE80E0B0Q37925009-C74FA347-814F-4824-816D-E27D0AD5728EQ37926750-E1EABC65-BD59-4993-B94F-20CAFF257F81Q37953465-6E8AAD54-598D-4E76-AE4C-CFF249E72E23Q37973397-3EA8700D-8E9C-4CC5-BFDE-32C1C4F20E5BQ37997963-49C4B9A7-6066-4A7B-A3BB-F6730FBF7E2AQ38005018-18EEC397-70C1-440C-8B15-9DCE4BA5502EQ38008466-F3161E93-1D1A-4E85-A09D-38E3B4DC029BQ38009746-4D7E792F-A194-4F67-8B2B-99D7D7F29ACBQ38025446-89930E34-59BE-47F1-9930-3EC2728AD21CQ38053481-533E6855-DD8F-4317-BB3F-85B9ADDE0D12Q38055245-F695CB23-AAA8-4587-8C04-65C71DFE4D58Q38071262-80891320-3540-4EC1-B874-5F4986EF21A6Q38079124-7241EA3C-E227-4AD4-A192-7DE1D8666FF9Q38081078-E1FD90DB-A23C-4AD6-B9E8-8BA6F8B28EAFQ38087381-95B6203B-2E7C-4F6C-9AC7-D1046832F7B3Q38132252-698FA70E-70A0-463B-AC17-79A208A00FE8Q38375641-1775DF36-872A-4662-864A-049D39310243Q38378830-F2D67869-C8DD-4E04-8B43-C5AF1F391A17Q38391222-BC9966DC-B8E9-4D0E-B95C-FB6A969D3CC7Q38542096-6FC29DFE-C9E1-47B5-96F4-E901A29AD9EAQ38800853-C5510910-E0BA-4261-9E89-2E24EE81E195Q38802062-52019A78-7857-4523-A716-04200E319A67Q38851769-4A112C34-3281-46C3-AE92-09995D1EF993Q41511099-9AC14872-F521-497B-87EF-E5C0C294B252Q41817424-43859CE8-BB97-4087-839B-0697BD1051DD
P2860
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A pharmacodynamic comparison o ...... es MellitUS (OPTIMUS)-3 Trial.
@ast
A pharmacodynamic comparison o ...... es MellitUS (OPTIMUS)-3 Trial.
@en
A pharmacodynamic comparison o ...... t Therapy In diabetes MellitUS
@nl
type
label
A pharmacodynamic comparison o ...... es MellitUS (OPTIMUS)-3 Trial.
@ast
A pharmacodynamic comparison o ...... es MellitUS (OPTIMUS)-3 Trial.
@en
A pharmacodynamic comparison o ...... t Therapy In diabetes MellitUS
@nl
prefLabel
A pharmacodynamic comparison o ...... es MellitUS (OPTIMUS)-3 Trial.
@ast
A pharmacodynamic comparison o ...... es MellitUS (OPTIMUS)-3 Trial.
@en
A pharmacodynamic comparison o ...... t Therapy In diabetes MellitUS
@nl
P2093
P2860
P921
P356
P1476
A pharmacodynamic comparison o ...... es MellitUS (OPTIMUS)-3 Trial.
@en
P2093
Alan D Michelson
Andrew L Frelinger
Baojin Zhu
Brian A Baker
Clement K Ojeh
Dominick J Angiolillo
Jorge F Saucedo
Joseph A Jakubowski
Juan Jose Badimon
Mark B Effron
P2860
P304
P356
10.1093/EURHEARTJ/EHQ494
P577
2011-01-20T00:00:00Z